But how will the complex J&J bispecific antibody fare in a market where oral small molecules are the norm?
Poziotinib unexpectedly succeeds in a lung cancer niche, but competition from Takeda must be tracked closely.
By the end of December poziotinib will deliver results that could justify the strategic refocusing Spectrum undertook this year.
Astra’s Caspian study is the star of next week’s World Lung conference, which has also given targeted approaches important supporting roles.
cMet emerges as the latest genetic mutation that could soon see targeted treatments become available.